A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
Abstract Monoclonal antibodies have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Still, there is a raising interest to develop advanced monoclonal antibody delivery systems able to tailor pharmacokinetics. Bevacizumab is a humanized imm...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/d53d29d91a274412b03b006cf9a016af |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|